Anorectic activities of serotonin uptake inhibitors: Correlation with their potencies at inhibiting serotonin uptake [formula omitted] and 3H-mazindol binding [formula omitted

Abstract

The mechanism of anorectic action of several serotonin uptake inhibitors was investigated by comparing their anorectic potencies with several biochemical and pharmacological properties and in reference to the novel compound SL 81. 0385. The anorectic effect of the potent serotonin uptake inhibitor SL 81.0385 (ED 50 = 4 mg/kg, i.p.) was potentiated by pretreatment with 5-hydroxytryptophan and blocked by the serotonin receptor antagonist metergoline. A good correlation (r = 0.98, p < 0.01) was obtained between the ED 50 values of anorectic action and the ED 50 values of serotonin uptake inhibition in vivo (but not in vitro ) for several specific serotonin uptake inhibitors. Most of the drugs tested displaced [ 3H]-mazindol from its binding to the anorectic recognition site in the hypothalamus, except the pro-drug zimelidine which was inactive (IC 50 > 100 μM). Excluding zimelidine, a good correlation (r = 0.835, p < 0.01) was obtained between the affinities of these drugs for [ 3H]-mazindol binding and their anorectic action indicating that their anorectic activity may be associated with an effect mediated through this site. Taken together these results suggest that the anorectic action of serotonin uptake inhibitors is directly associated to their ability to inhibit serotonin uptake and thus increasing the synaptic levels of serotonin. The interactions of these drugs with the anorectic recognition site labelled with [ 3H]-mazindol is discussed in connection with the serotonergic regulation of carbohydrate intake.